| Identification | Back Directory | [Name]
T-448 free base | [CAS]
1597426-52-2 | [Synonyms]
T-448 free base
T 448 free base,T448 free base
Benzamide, 3-[(1S,2R)-2-(cyclobutylamino)cyclopropyl]-N-(5-methyl-1,3,4-thiadiazol-2-yl)- | [Molecular Formula]
C17H20N4OS | [MDL Number]
MFCD34469355 | [MOL File]
1597426-52-2.mol | [Molecular Weight]
328.43 |
| Hazard Information | Back Directory | [Uses]
T-448 free base is a specific, orally active and irreversible inhibitor of lysine-specific demethylase 1 (LSD1, an H3K4 demethylase), with an IC50 of 22 nM. T-448 free base enhances H3K4 methylation in primary cultured rat neurons[1]. | [in vivo]
T-448 has minimal impact on the LSD1-GFI1B complex and a superior hematological safety profile in mice via the generation of a compact formyl-FAD adduct. T-448 increases brain H3K4 methylation and partially restored learning function in mice with NMDA receptor hypofunction[1].
T-448 increases H3K4 methylation in the brain without causing hematological side effects even at 100 mg/kg[1].
| Animal Model: | NR1-hypo mice[1]. | | Dosage: | 1, 10 mg/kg. | | Administration: | Orally, 3 weeks. | | Result: | Dose-dependently increased the H3K4me2 levels around Bdnf, Arc, and Fos genes in
the mouse hippocampus.
Resulted in partial but statistically significant and dosedependent rescue effects on the rate of correct choices in NR1-hypo mice.
|
| [References]
[1] Matsuda S, et al. T-448, a specific inhibitor of LSD1 enzyme activity, improves learning function without causing thrombocytopenia in mice. Neuropsychopharmacology. 2018 Dec 22. DOI:10.1038/s41386-018-0300-9 |
|
|